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Introduction
Lung cancer is the most common cancer. In 2018, there 
were an estimated 2.09 million cases of lung cancer and 1.76 
million deaths due to lung cancer worldwide (1). Squamous 
cell lung cancer (SqCC) is a distinct histological subtype 
of lung cancer that accounts for approximately 25–30% of 
all lung cancers, following adenocarcinomas which account 
for approximately 40% of all lung cancers. SqCC is more 
commonly located in the central lung and frequently 
invades the proximal bronchus and large blood vessels (2). 
Compared with the stage of nonsquamous non-small cell 
lung cancers, SqCCs are often at an advanced stage at the 
time of diagnosis and this is frequently accompanied by 
comorbidities such as chronic obstructive lung disease and 
heart disease, which makes SqCC challenging to treat (3-6). 
Moreover, activating mutations such as the epidermal 
growth factor receptor and anaplastic lymphoma kinase 
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fusion, which lead to remarkable changes in the treatment 
of lung adenocarcinoma, are typically not present in SqCC 
and targeted agents that are used with adenocarcinoma are 
largely not effective with SqCC (7-10).
Through tumor genome profiling, via the development 
of next-generation sequencing, detailed information on 
carcinogenesis, including tumor development, progression, 
therapeutic response, and drug resistance, has been 
obtained. The discoveries of multiple studies, based on 
tumor sequencing, suggest that “intratumor heterogeneity”, 
which describes the uneven distribution of genetically 
diverse tumor subpopulations within a tumor, plays a key 
role in treatment failure and drug resistance (11-14). 
The cause of intratumor heterogeneity can be explained 
by genomic instability that results from exposure to 
exogenous mutagens (such as UV radiation and exposure to 
cigarette smoke) and aberrations in endogenous processes 
(such as DNA replication, error repair, and oxidative stress), 
which are maintained by selective processes (13,15). 
Methods for estimating intratumoral heterogeneity are: 
extensive tumor dissection (16-18), ultradeep sequencing of 
mutations (19), and single-nucleus sequencing by isolating 
individual nuclei (20,21). Most of these methods are not 
only technically difficult to perform but are also practically 
difficult to carry out in clinical settings. In this study, we 
adopted a method to infer the number of subclones from 
variant allele frequency (VAF), which could be more feasible 
to apply clinically than the methods mentioned. 
VAF is the percentage of sequence reads that match a 
specific DNA variant, divided by the overall coverage at that 
locus (22). VAF represents the percentage of tumor cells 
that harbor a specific mutation, assuming a relatively pure 
tumor sample (23,24). By clustering VAF, the number of 
subclones in the tumor can be inferred and heterogeneity can 
be estimated. Mutant-allele tumor heterogeneity (MATH) 
score, which is calculated from the ratio of the width to the 
center of the distribution of the VAF in the tumor-specific 
mutated loci, could provide a straightforward measure of 
one type of intratumor heterogeneity (25).
In this study, we investigated whether the number of 
subclones that represent intratumor heterogeneity is related 
to genomic mutations and cancer stage. We also investigated 
the genes that are related to intratumor heterogeneity. 
Methods
Data acquisition 
The results shown here are based upon data generated by 
The Cancer Genome Atlas (TCGA) Research Network: 
https://www.cancer.gov/tcga. The following data were 
downloaded from 504 SqCC cases shared in the TCGA 
project: (I) mutation annotation format (MAF) files for 
single nucleotide variants (SNV) analyzed with VarScan2 
variant Aggregation and Masking workflow; (II) Masked 
Copy Number Segment analyzed with Affymetrix SNP 6.0; 
(III) RNA sequencing analyzed with HTSeq; (IV) Clinical 
information. Of the 504 The Cancer Genome Atlas-Lung 
Squamous Cell Carcinoma (TCGA-LUSC) cases, 488 
had SNV, copy number segment, RNA sequencing, and 
clinical information, which made them eligible for study 
analyses. The Tumor Sample Barcodes of those cases were 
confirmed and analyzed based on the data obtained from 
the primary solid tumor. Among them, three cases (TCGA-
18-3409, TCGA-90-A4ED, and TCGA-21-1079), which 
had exceptionally high numbers of mutations and four cases 
(TCGA-34-2604, TCGA-34-2605, TCGA-34-2609, and 
TCGA-77-8146) in which the SNVs were 0, were excluded. 
Finally, 481 cases were recruited for this analysis (Table S1). 
To improve the positive predictive value of the low allele 
frequency, SNVs with a total read depth of less than 40 
and SNV data that did not meet the limit of detection as 
suggested by Shin et al. were excluded (24).
Calculations of subclone numbers and differentially 
expressed gene (DEG) analysis 
To estimate the number of subclones SciClone (http://
github.com/genome/sciclone) was used, which estimates 
the number of subclones by clustering a variant with 
similar allele frequencies (26). Computational efficiency is 
achieved by clustering VAFs using a variational Bayesian 
mixture model (27). To identify genes related to intratumor 
heterogeneity that were represented by the number of 
subclones, DEG analysis between high clone and low clone 
groups was performed. Patients who had five subclones 
were paired with patients who had one subclone. Potential 
confounding variables such as age, sex, stage, and smoking 
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Table 1 Demographic characteristics of the study cases.
Patients characteristics N=481





















Values are expressed as the median (interquartile range) or 
number (%).
status were adjusted by the propensity matching method 
while pairing the two groups using the “MatchIt” package 
in R. Analyzing the DEG between high clone and low clone 
groups was demonstrated using the “DEseq2” package in 
R. When the ratio of gene expression in the experimental 
groups to the control group was more than 2 or less than 
1/2 and the P-adjusted value was less than 0.05, it was 
considered a significant DEG and further analysis was 
performed. The ontology of the DEG was confirmed using 
ToppGene (https://toppgene.cchmc.org/). 
Statistical analysis 
The distribution of variables was examined using the 
Shapiro-Wilk test. Continuous variables of three or more 
groups were analyzed using the Kruskal-Wallis test. 
Categorical variables were analyzed using the chi-squared 
distribution and Fisher’s exact test. In all cases, P-values 
<0.05 were considered statistically significant. Statistical 
analyses were performed using R statistical software, version 




Data from 481 LUSCs in stages I–IV that had not 
experienced any treatment for lung cancer were collected 
from the TCGA. The demographic characteristics are 
described in Table 1. The median age of the study cohort 
was 68.6 (62.3–73.9) years and 356 (74.0%) were male. The 
study population was comprised of 232 cases (48.2%) in 
stage I, 157 (32.6%) in stage II, 81 (16.8%) in stage III, and 
7 (1.4%) in stage IV. Regarding smoking status, 453 cases 
(94.2%) were ever-smokers, 18 (3.7%) were never smoked, 
and the smoking status of 10 (2.1%) were unavailable. The 
data of smoking amount (packs-years) were available in 407 
cases among ever smokers and the median was 54.0 (21.0–
70.0) pack-years. 
Number of subclones constituting the primary tumor was 
related to the number of variants and tumor stage
Whole exome sequencing of 481 LUSCs identified a total 
of 117,869 variants with a median of 209.0 (128.0–319.0) 
variants per tumor (Figure 1A). SNVs occupied most of 
these variations, followed by deletions and insertions. When 
the number of subclones that comprised the single primary 
tumor was inferred by SciClone (Representative figures are 
shown in Figure 1B,C), the median number of subclones 
that comprised a tumor was 2 (1-3). The total variation 
in a tumor showed a significant positive correlation with 
the number of subclones in a tumor (σ=0.388, P-value 
<0.001, Figure 1D) and when these variations were classified 
into SNVs and indels, they showed significant positive 
correlations with the number of subclones (σ=0.389, 
P-value <0.001; σ=0.241, P-value <0.001, respectively, 
Table 2). According to the variant effect predictor (VEP) as 
presented in the TCGA, the variants were further classified 
into high, moderate, low impact variants, and modifier 
and analyzed according to the number of subclones. The 
number of high and moderate impact variants increased 
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Figure 1 Relationship between mutations and subclones that constituted a tumor in TCGA-LUSC. (A) Distribution of total mutations 
in TCGA-LUSC; (B,C) representative figure used for clonality estimation. These figures were derived from the SciClone package; (D) a 
violin plot showing the total number of mutations according to the number of subclones. The total number of mutations and the number 
of subclones were positively correlated (Pearson's correlation efficiency, σ=0.376, P-value <0.001); (E) all mutations detected were classified 
according to VEP—high, moderate, low impact variant, and modifier—and compared according to the number of subclones; (F) scatter plot 
showing the relationship between the tumor stage and the number of subclones. Tumor stage and the number of subclones were positively 
correlated (Pearson’s correlation efficiency, σ=0.099, P-value =0.030).
Median: 209[128–319]
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as the number of subclones increased (σ=0.357, P-value 
<0.001; σ=0.383, P-value <0.001, respectively; Figure 1E, 
Table 2). Because the staging system is still the most useful 
parameter for predicting the clinical outcome in patients 
with lung cancer, we compared the number of subclones 
with the stage of lung cancer and discovered that there was 
a significant positive correlation between the number of 
subclones and stage (σ=0.099, P-value =0.030, Figure 1F). 
These results suggested that the number of subclones that 
comprised a primary tumor was positively related to the 
number of variants and stage of the corresponding tumor, 
which suggested that the number of subclones reflected the 
biological aspect of a tumor.
Gender was related to the number of subclones
To determine the factors associated with the increased 
number of subclones, we examined the relationship between 
the number of subclones and clinical parameters that were 
known to be associated with SqCCs. Because smoking is 
one of the main causes of lung cancer by causing C > A 
transversions of DNA, we divided the patients into non-
smokers and ever-smokers and compared the number of 
subclones between the two groups. Tumors of ever-smokers 
consisted of a significantly larger number of subclones than 
those of never-smokers (2.2 vs. 1.7, P-value =0.043, Kruskal-
Wallis rank-sum test, Figure 2A, http://cdn.amegroups.
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cn/static/application/b0dcd306dde9c330e80f00e4985ce5
5f/tlcr-19-589-1.pdf). Therefore, we further investigated 
whether the expansion of clone number was dependent on 
the amount of smoking and discovered that there was no 
significant relationship between pack-years and the number 
of subclones (Figure 2B). As age-related mutations were 
observed in most malignancies, including lung cancer, and 
there was a significant positive correlation between lung 
cancer incidence and age (28), the relationship between age 
at diagnosis of lung cancer and the number of subclones was 
investigated. Age at diagnosis and number of subclones did 
not show a significant correlation (Figure 2C). These results 
suggested that smoking and aging had no major effect on 
the propagation of subclones.
Finally, the influence of gender on the increase in 
subclone number was investigated. The number of 
subclones that constituted a tumor was significantly higher 
in patients who were male than those who were female 
(P=0.001, Wilcoxon rank-sum test, Figure 2D). To verify 
whether gender was a truly significant factor that influenced 
the number of subclones, 105 female TCGA-LUSC cases, 
which had identifiable smoking status, were 1:1 matched 
with male cases considering age, pack-years, and stage 
using the “MatchIt” R package (Figure S1). In this analysis, 
male tumors consisted of significantly more subclones than 
female LUSCs, which indicated that gender is the sole 
parameter related to the number of subclones (2.25 vs. 1.86, 
male vs. female: P-value =0.002, Welch Two Sample t-test). 
Inferring clonal expansion via DEG 
To uncover the possible etiology that increased the number 
of subclones that constituted a tumor, an additional analysis 
was performed using RNA sequencing data. Using the 
propensity score matching of the “MatchIt” R package, 
the LUSC cases in which tumors were composed of five 
subclones, which is the largest number of subclones among 
the study cases, were matched with those in which the tumor 
was composed of a single subclone by age, sex, pack-years, 
and stage (Figure 1B, http://cdn.amegroups.cn/static/appli
cation/92369042f5e4ab643e2c8b83670a2049/tlcr-19-589-
2.pdf). After performing three independent matching and 
DESeq2 analyses, we obtained a set of intersections from 
the results of each analysis and performed gene ontology 
analysis using ToppGene (https://toppgene.cchmc.org/). 
DEG analysis revealed that 291 genes were upregulated 
and 102 genes were downregulated in the tumors composed 
of 5 subclones compared to single subclone tumors 
(http://cdn.amegroups.cn/static/application/ff5c28125
7c4bebadda9eaff792d56a5/tlcr-19-589-3.pdf). Among 
these, the most upregulated genes were UGT1A10, SRY, 
FDCSP, MRLN, and EREG in order of magnitude of 
overexpression (Table 3,Figure 2E) and the overexpressed 
genes were significantly enriched in the (I) tumor necrosis 
factor superfamily cluster of differentiation molecules, 
(II) C-type lectin domain family, (II) fibronectin type III 
domain that contained interleukin receptors, (IV) EF-
Table 2 Relationship between the number of subclones and variants
Number of 
subclones




Subtypes of mutations 











Indel 1.0 (0.0–1.5) 1.0 (0.0–2.0) 1.0 (0.0–3.0) 2.0 (1.0–3.0) 3.0 (1.0–4.0) 0.241 <0.001
Variant according to the VEP
High 12.0 (5.0–19.0) 18.0 (10.0–27.0) 26.0 (19.0–34.0) 30.0 (22.0–37.0) 27.0 (23.5–39.0) 0.357 <0.001











Low 30.0 (16.5–48.0) 43.0 (30.3–66.8) 58.0 (45.0–88.0) 67.0 (49.0–84.0) 72.0 (62.8–92.3) 0.379 <0.001
Modifier 10.0 (4.0–17.0) 15.0 (10.0–24.0) 23.0 (17.0–36.0) 27.0 (19.0–34.0) 32.0 (28.3–37.5) 0.401 <0.001
*, P-value was obtained by Kruskal-Wallis test. SNV, single nucleotide variants; VEP, variant effect predictor.
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Figure 2 The relationship among clinical parameters and the number of subclones and differential expression genes according to the 
number of subclones in TCGA-LUSC. (A) A box plot showing the difference in the number of subclones according to smoking history 
(2.2 vs. 1.7, P-value =0.043, Kruskal-Wallis rank-sum test); (B) a violin plot showing the amount of smoking (packs/year) according to the 
number of subclones. The amount of smoking was not correlated with the number of subclones; (C) a violin plot showing age according 
to the number of subclones. There was no correlation between age at diagnosis and the number of subclones that comprised a tumor; (D) 
a violin plot showing the number of subclones according to sex. The number of subclones was significantly higher in males than that in 
females (P=0.001, Wilcoxon rank-sum test); (E) volcano plot of differentially expressed genes between cases comprised of five subclones and 
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hand domain that contained S100 calcium-binding proteins 
(Table S2). The biological function of these upregulated 
genes was strongly enriched for the positive regulation 
of immune processes and inflammatory responses. The 
downregulated genes were LINC00221, FGF19, CPLX2, 
LINC02582 ,  and ABCC2  in order of magnitude of 
downregulation; however, these downregulated genes were 
not significantly enriched for specific gene families. Because 
a relationship was found between sex and the increase in 
subclone number, the DEG between the two genders was 
obtained by matching pack-year, age at diagnosis, and 




dc314/tlcr-19-589-5.pdf). Then, the intersection of DEGs 
upregulated in the male LUSCs and those in which the 
tumor was comprised of five subclones were obtained. 
Six DEGs were observed, five of which were upregulated 
and one of which was downregulated in both groups 
(Figure 2E,Table S3). The biological function of upregulated 
genes LRRC38 ,  FDCSP ,  SRY ,  FAM181A-AS1 ,  and 
PICSAR was closely related to the positive regulation of 
potassium ion transmembrane transport and male gender 
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Table 3 Top 10 upregulated and bottom 10 downregulated differentially expressed genes in the high clone group compare to the low clone group





Top 10 upregulated differentially expressed genes in high clone group compare to low clone group
1 ENSG00000242515 UGT1A10 Conjugate and eliminate toxic xenobiotics and 
endogenous compounds
6.7999 0.0002
2 ENSG00000184895 SRY Transcriptional regulator that controls a genetic 
switch in male development
5.9184 0.0052
3 ENSG00000181617 FDCSP A secreted mediator acting upon B-cells 5.7466 0.0002
4 ENSG00000227877 MRLN Inhibits activity of ATP2A1/SERCA1 ATPase 
in sarcoplasmic reticulum by decreasing the 
apparent affinity of the ATPase for Ca2+
5.3942 0.0008
5 ENSG00000124882 EREG Ligand of the EGF receptor/EGFR and ERBB4 4.9484 0
6 ENSG00000258584 FAM181A-AS1 FAM181A anti-sense RNA 4.5072 0.0095
7 ENSG00000272620 AFAP1-AS1 AFAP1 changes in actin filament integrity and 
induce lamellipodia formation
4.3437 0.0053
8 ENSG00000181333 HEPHL1 A ferroxidase involved in copper transport and 
homeostasis
4.2781 0.0008
9 ENSG00000186847 KRT14 KRT5-KRT14 filaments self-organization into 
large bundles
4.2729 0.0007
10 ENSG00000175315 CST6 Inhibition of cathepsin B 4.2129 0.0001
Bottom 10 downregulated differentially expressed genes in high clone group compare to low clone group
1 ENSG00000270816 LINC00221 long intergenic non-protein coding RNA 221 –9.8765 0.0001
2 ENSG00000162344 FGF19 Suppression of bile acid biosynthesis through 
down-regulation of CYP7A1 expression
–7.9493 0.0012
3 ENSG00000145920 CPLX2 Negatively regulates the formation of synaptic 
vesicle clustering at active zone to the 
presynaptic membrane in postmitotic neurons
–7.4858 0.004
4 ENSG00000261780 LINC02582 long intergenic non-protein coding RNA 2582 –6.8188 0.0144
5 ENSG00000023839 ABCC2 Mediates hepatobiliary excretion of numerous 
organic anions
–5.7525 0
6 ENSG00000007350 TKTL1 Catalyzes the transfer of a two-carbon ketol 
group from a ketose donor to an aldose 
acceptor
–5.7078 0.0038
7 ENSG00000189064 GAGE2C Antigen, recognized on melanoma by 
autologous cytolytic T-lymphocytes
–5.5264 0.0026
8 ENSG00000242512 LINC01206 long intergenic non-protein coding RNA 1206 –5.3282 0.0125
9 ENSG00000136574 GATA4 Transcriptional activator playing a key role in 
cardiac development and function
–4.707 0.0004
10 ENSG00000009709 PAX7 Transcription factor playing a role in 
myogenesis through regulation of muscle 
precursor cells proliferation
–4.2093 0.0264
†, description was adapted from GeneCards (https://www.genecards.org/).
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differentiation. However, the limited number of common 
genes observed in DEG analysis in male to female LUSC 
tumors and DEG analysis according to the number of 
clones suggested that masculinity did not play a critical role 
in clonal expansion. 
Overa l l ,  pos i t i ve  regula tor  genes  invo lved  in 
inflammatory and immune responses were significantly 
overexpressed in the LUSC tumors with high clone 
numbers. 
Discussion
In this study, we discovered that intratumor heterogeneity 
inferred from the number of subclones that constituted a 
tumor positively correlated with the number of somatic 
variants and cancer stage. The number of subclones 
was significantly higher in males than that in females, 
whereas smoking status and age did not show a significant 
relationship with the number of subclones. This suggested 
that masculinity was a factor that affected clonal expansion. 
In DEG analysis, which was performed to identify genes 
related to clonal expansion, genes, whose function is 
related to the positive regulation of immune processes and 
inflammatory responses, were enriched in the LUSCs that 
were composed of high subclone numbers. However, it 
was assumed that masculinity did not play a critical role in 
clonal expansion in DEG analysis. 
There are several statistical models for the inference 
of clonal population structure in a tumor, including 
SciClone’s (26) variational Bayesian mixture model, 
MAFtools’ (29) Gaussian mixture, and PyClone’s (30) beta-
binomial emission densities. Among these statistical models, 
we calculated the number of subclones with Sciclone. The 
MATH scores, calculated from the ratio of the width to the 
center of the distribution of VAF to represent intratumor 
heterogeneity, were evaluated in the study population. 
There was a significant correlation between the number 
of subclones inferred from either SciClone or MAFtools 
and MATH score (Figure S2). The MATH score in this 
study was positively correlated with the number of somatic 
variants and cancer stage and the median was significantly 
higher in males than that in females, whereas smoking and 
age did not show a significant correlation with the MATH 
score. These were the same results as those evaluated by 
the number of subclones calculated by SciClone (data not 
shown), which suggested there is no significant difference 
among the results obtained by different methods of 
inferring intratumoral clonality.
Despite interest that heterogeneity could be the main 
cause of treatment failure, clinical indicators that properly 
reflect heterogeneity are not widely used in the medical 
field. In this study, by analyzing genome and transcriptome 
data of 481 TCGA-LUSC cases, we revealed that 
masculinity could affect clonal expansion, whereas smoking 
status and age have no major effect on the propagation 
of heterogeneity. To verify these results, we analyzed the 
mutational signature suggested by Alexandrov et al. (28). 
In 481 TCGA-LUSC patients with high clonality, whose 
tumors consisted of five clones, only Signature 4 (smoking) 
and Signature 2 (APOBEC) were extracted in mutational 
signature analysis, which is no different to the signatures 
observed in the TCGA-LUSC cases (Figure S3), which 
suggests that the effect of specific mutational signatures on 
clonal expansion are insignificant.
Representative genes that were overexpressed in tumors 
that consisted of a high number of subclones compared 
to single clone tumors are UGT1A10, SRY, FDCSP, 
MRLN, and EREG. The most significant difference 
between the tumors is in regard to UGT1A10. UDP-
glucuronosyltransferases (UGTs), estimated as a gene 
involved in clonal expansion by DEG analysis, catalyzes 
the conjugation of glucuronic acid with the polar groups 
(e.g., hydroxyl, thiol, carboxyl, and amines) from xenobiotic 
substances to facilitate their elimination as well as the 
elimination of endogenous molecules, such as bile acids 
and hormones (31). To date, many studies were performed 
to reveal the links between UGTs and cancer risk, based 
on the idea that the alterations of UGT function may 
significantly influence the clearance of carcinogens and sex 
hormones. UGT1A1, 1A6, 1A7, and 1A8 are involved in 
the metabolism of dietary carcinogens and genotypes with 
low functional properties would highly increase the risk of 
colorectal, esophageal, and proximal digestive tract cancers 
(31-33). Estrogen-metabolism related UGT1A1, 1A6, and 
2B4 and androgen-metabolism related 2B15 and 2B17 genes 
are closely related to breast, endometrial, and prostate 
cancers (34-37). UGT1A6, 1A7, 2B7, and 2B17 are involved 
in the metabolism of tobacco carcinogens and are linked to 
lung, oropharyngeal, and bladder cancers (38-40). Although 
the majority of studies are related to the low functional 
activities of UGTs and increased cancer risk, there are also 
several studies that reported higher UGT activities with 
higher cancer risk and decreased UGT activities with lower 
cancer risk (41,42). UGTs are the key metabolic enzymes 
involved in not only the detoxification of many carcinogens 
but also the elimination of antioxidant, anti-proliferative 
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substances, and therapeutic drugs. An imbalance in UGT 
activity, both upregulated and downregulated, can be 
interpreted in association with carcinogenesis based on 
previous studies. In the TCGA-LUSC cases matched by 
sex, age, and stage, UGT was highly upregulated in the high 
clonality group and it was inferred that the high functional 
activity of UGT was related to the clonal expansion 
of SqCC. This requires further research to determine 
whether increased activity of UGT derives or assists clonal 
expansion.
This study has a few limitations. Firstly, none of the 
methods for the prediction of heterogeneity is complete. 
Single-cell analysis may be ideal for evaluating intratumoral 
heterogeneity, but it has many challenges, including 
difficulty in the selection of target lesion and analyzing 
only 5,000 to 10,000 cells per selected area, which suggest 
that this method also has the same common limitations. 
Secondly, due to the lack of data, we could not demonstrate 
the association between clonality and outcome (disease 
recurrence, survival, and treatment responses). However, by 
the result that patients with higher numbers of subclones 
showed more advanced cancer stages, we could infer poor 
prognosis with high clonality indirectly. 
Conclusions
Intratumor heterogeneity represented by the number of 
subclones was positively correlated with somatic mutation 
burden and cancer stage. Considering that the tumor 
mutation burden predicts the response of the immune 
checkpoint inhibitors, it could be inferred that there is 
a relationship between the number of subclones and the 
immune response. The number of subclones was higher in 
males than in females, whereas smoking status and age were 
not correlated with clonality. In DEG analysis, a significant 
enrichment in genes whose function is related to the 
positive regulation of immune processes and inflammatory 
responses in high clone tumors compared to that in single 
clone tumors. In-depth studies are required to determine 
whether the overexpression of the positive regulation of 
immune process and inflammatory response genes in high 
clone number tumors is a driver of clonal expansion. 
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Table S1 Relationship between the number of subclones and clinical parameters
Number of subclones Never-smoker (n=18) Ever-smoker (n=453) P-value* Female (n=125) Male (n=356) P-value*
1 11 (61.1) 128 (28.3) 0.037 46 (36.8) 97 (27.2) 0.013
2 2 (11.1) 177 (39.1) 53 (42.4) 129 (36.2)
3 4 (22.2) 100 (22.1) 20 (16.0) 87 (24.4)
4 1 (5.6) 36 (7.9) 6 (4.8) 31 (8.7)
5 0 (0.0) 12 (2.6) 0 (0.0) 12 (3.4)
Values are expressed as numbers (%). *, P-value was obtained by the Kruskal-Wallis test.
Figure S1 Distribution of propensity scores. (A) Distribution of propensity scores in 1:1 matching of male and female LUSCs adjusting for 
age, packs/year, and stage; (B) That of LUSC cases whose tumor was comprised of five subclones and those of a single clone adjusting for 
age, sex, smoking history, and stage. For (B), a representative image from three independent matchings is shown.
BA
Supplementary
Table S2 List of gene families differentially expressed in male TCGA-LUSC cases and high clone cases
Group 
description







Minor histocompatibility antigens|FERM 
domain containing
6.61E-09 3.63E-07 1.67E-06 3.63E-07 6 51
Keratins, type II 6.14E-05 1.69E-03 7.75E-03 3.38E-03 3 27
S100 calcium binding proteins|S100 fused 
type protein family
1.67E-04 3.06E-03 1.40E-02 9.17E-03 2 7
Neuropeptide receptors 3.55E-04 4.89E-03 2.24E-02 1.95E-02 2 10
Downregulated 
in male
Potassium voltage-gated channels 1.52E-07 2.03E-05 1.11E-04 2.03E-05 7 40
Upregulated in 
high clone 
CD molecules|TNF superfamily 4.39E-18 5.26E-16 2.83E-15 5.26E-16 29 394
C-type lectin domain family 2.42E-07 1.45E-05 7.81E-05 2.91E-05 7 47
Fibronectin type III domain 
containing|Interleukin receptors
2.34E-06 9.35E-05 5.02E-04 2.80E-04 6 42
S100 calcium binding proteins|EF-hand 
domain containing
3.80E-05 1.01E-03 5.41E-03 4.56E-03 4 21
Histocompatibility complex|C1-set domain 
containing
4.20E-05 1.01E-03 5.41E-03 5.04E-03 5 42
Ig like domain containing|IL receptors|TIR 
domain containing
8.19E-05 1.64E-03 8.80E-03 9.83E-03 9 193
Scavenger receptors 1.07E-04 1.83E-03 9.82E-03 1.28E-02 4 27
CD molecules|Tumor necrosis factor 
superfamily




Table S3 Intersection of DEGs according to the number of subclones and gender
Gene expression EnsemblGeneID Gene name
Base Mean  
(mean*)
Log2 fold change 
(mean*)





5 clones vs. single clone
Up-regulated  
genes
ENSG00000162494 LRRC38 10.92362714 3.030599079 0.814403088 3.710007249 3.00E-04 0.0145
ENSG00000181617 FDCSP 2535.113848 5.746592724 1.101206236 5.207333935 0 2.00E-04
ENSG00000184895 SRY 7.418201974 5.918376103 1.46607645 4.035039645 1.00E-04 0.0052
ENSG00000258584 FAM181A-AS1 23.81093098 4.507235807 1.023438449 4.471050273 1.00E-04 0.0095
ENSG00000275874 PICSAR 22.52969236 3.327571162 0.815326183 4.077911912 1.00E-04 0.0048
Down-regulated 
genes




ENSG00000162494 LRRC38 43.79789759 1.809990005 0.347772452 5.204523805 1.94E-07 6.25E-05
ENSG00000181617 FDCSP 1596.007483 2.721143884 0.392054803 6.940723236 3.90E-12 3.19E-09
ENSG00000184895 SRY 4.152815452 5.351222118 0.499180824 10.72000738 8.20E-27 1.03E-23
ENSG00000258584 FAM181A-AS1 11.42917054 1.163042951 0.309919148 3.752730212 0.000174919 0.013203229
ENSG00000275874 PICSAR 29.47008141 1.652827778 0.378815681 4.36314509 1.28E-05 0.00196214
Down-regulated 
genes
ENSG00000149294 NCAM1 210.5695647 –1.258054818 0.239135814 –5.260838165 1.43E-07 NA
*, mean value from three independent matching and DEG analyses; **, standard error of log2 fold change; †, Wald statistics. DEG, differentially expressed genes; NA, not 
available.
Figure S2 Relationship between MATH score and tumor stage. (A) Scatter plot showing the relationship between the number of subclones and MATH score. Number of 
subclones and MATH score were positively correlated (Pearson's correlation efficiency, σ=0.251, P-value <0.001); (B) scatter plot showing the relationship between the tumor 
stage and MATH score. Tumor stage and the MATH score were positively correlated (Pearson's correlation efficiency, σ=0.101, P-value =0.029).
BA
Figure S3 Comparison of enriched mutational signatures. Enriched mutational signature in high clonality group (A) and all TCGA-LUSC 
cases (B). Signature 4 (smoking) and Signature 2 (APOBEC) were derived from the group whose tumor consisted of five clones. Differences 
in mutational patterns between APOBEC enriched and non-APOBEC enriched samples in the high clonality group (C) and in all TCGA-
LUSC cases (D).
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